4SC AG: 6 upcoming conferences and roadshows

Planegg-Martinsried, Germany, 12 September 2018 – 4SC AG (4SC, FSE Prime Standard: VSC) today announced its participation at upcoming conferences and roadshows. 4SC’s management and scientists will be available for one-on-one meetings at these events.


28. Deutscher Hautkrebskongress (ADO)

13-15 September 2018

Stuttgart, Germany


Raiffeisenbank-AnlegerForum (event for German retail investors)

13 September 2018

Eching bei Landshut, Germany


Berenberg and Goldman Sachs Seventh German Corporate Conference

24-26 September 2018

Munich, Germany


EORTC CLTF Meeting | Cutaneous Lymphoma Group Meeting 2018

27-29 September 2018

St. Gallen, Switzerland


Israel Non Deal Roadshow

15-16 October 2018



ESMO 2018 Congress

19-23 October 2018

Munich, Germany


About 4SC

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises three key drug candidates in various stages of preclinical and clinical development: resminostat, domatinostat (4SC-202) and 4SC-208.

4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself.

4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 45 employees as of 30 June 2018 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72).

Forward-looking information

Information set forth in this press release contains forward-looking statements, which involve risks and uncertainties. The forward-looking statements contained herein represent the judgement of 4SC as of the date of this press release. Such forward-looking statements are neither promises nor guarantees, but are subject to a variety of risks and uncertainties, many of which are beyond 4SC’s control, and which could cause actual results to differ materially from those contemplated in these forward-looking statements. 4SC expressly disclaims any obligation or undertaking to release any updates or revisions to any such statements to reflect any change in its expectations or any change in events, conditions or circumstances on which any such statement is based.

Share this page:

Follow us on: